This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

proofread

Mivavotinib for relapsed/refractory B-cell lymphoma

Oncotarget | Mivavotinib for Relapsed/Refractory B-cell Lymphoma (Updated)
Kaplan–Meier curve for estimated median DOR in the DLBCL combined cohort (response-evaluable population). Credit: 2023 Gordon et al.

In a new research paper published in Oncotarget, researchers report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib. They present data for the overall cohort of lymphoma patients and the subgroup of patients with diffuse large B-cell lymphoma (DLBCL), including an expanded cohort not included in the initial report.

"Mivavotinib (TAK-659/CB-659) is an investigational, oral, reversible, potent dual inhibitor of spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 (FLT3). SYK is an essential component of the B-cell receptor signaling pathway; abnormal SYK signaling has been implicated in the pathogenesis of DLBCL and several other B-cell malignancies," say the researchers.

Patients with relapsed/refractory for which no was available received mivavotinib 60–120 mg once daily in 28-day cycles until /unacceptable toxicity. A total of 124 patients with lymphoma, including 89 with DLBCL, were enrolled. Overall response rates (ORR) in response-evaluable patients were 45% (43/95) and 38% (26/69), respectively. Median duration of response was 28.1 months overall and not reached in DLBCL responders.

In subgroups with DLBCL of germinal center B-cell (GCB) and non-GCB origin, ORR was 28% (11/40) and 58% (7/12), respectively. Median progression free survival was 2.0 and 1.6 months in the lymphoma and DLBCL cohorts, respectively. Grade ≥3 treatment-emergent adverse events occurred in 96% of all , many of which were limited to asymptomatic laboratory abnormalities; the most common were increased amylase (29%), neutropenia (27%), and hypophosphatemia (26%).

"These findings support SYK as a potential therapeutic target for the treatment of patients with B-cell lymphomas, including DLBCL," note the researchers.

More information: Leo I. Gordon et al, Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659), Oncotarget (2023). DOI: 10.18632/oncotarget.28352

Journal information: Oncotarget
Provided by Impact Journals LLC
Citation: Mivavotinib for relapsed/refractory B-cell lymphoma (2023, February 1) retrieved 28 March 2024 from https://medicalxpress.com/news/2023-02-mivavotinib-relapsedrefractory-b-cell-lymphoma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Potent results from a new immune treatment seen in patients with hard-to-treat blood cancers

2 shares

Feedback to editors